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1. INTRODUCTION {#jcmm14257-sec-0001}
===============

Colorectal cancer (CRC) is the third most common cancer worldwide and accounts for 10% of all new cancer diagnoses. Unfortunately, 20% of patients diagnosed with CRC have metastatic disease.[1](#jcmm14257-bib-0001){ref-type="ref"} The recurrence of CRC is mostly a time‐limited phenomenon; 40%‐50% of recurrence events become apparent within the first year after the initial surgical resection.[2](#jcmm14257-bib-0002){ref-type="ref"} In addition, the earlier the relapse occurs, the poorer are the overall survival rates.[3](#jcmm14257-bib-0003){ref-type="ref"} The growth and proliferation of metastatic CRC (mCRC) depends essentially on two signalling pathways: the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways. Although substantial progress has been made in the past decades regarding the management of this disease, including surgical treatment, radiotherapy and chemotherapy, patients with advanced CRC continue to receive a poor prognosis and have a high death rate.[4](#jcmm14257-bib-0004){ref-type="ref"} Consequently, a better understanding of the molecular mechanisms underlying CRC development and progression is urgently needed. More specifically, oligonucleotide therapies using small interfering RNAs, short hairpin RNAs, RNA aptamers and ribozymes have received considerable attention because they enable the targeted delivery of antitumour drugs without significant toxicity or other systemic side effects.[5](#jcmm14257-bib-0005){ref-type="ref"}, [6](#jcmm14257-bib-0006){ref-type="ref"}, [7](#jcmm14257-bib-0007){ref-type="ref"} In this study, we focused on the use of microRNA (*miRNA*) as a potential therapy for CRC.

In humans, *miR‐148a* with 68 nucleotide sequences is located on chromosome 7p15.2. *miR‐148a* performs the common functions of many miRNA species and is implicated in a series of biological processes including cellular proliferation, apoptosis, metastasis and invasion.[8](#jcmm14257-bib-0008){ref-type="ref"} In breast cancer cells, the ERK signalling pathway is the key downstream pathway of hypoxia‐inducible factor‐1α (HIF‐1α) and plays an important role in angiogenesis and cancer development. The down‐regulation of *miR‐148a* expression activates the ERK signalling pathway to increase HIF‐1α and VEGF expression.[9](#jcmm14257-bib-0009){ref-type="ref"} Moreover, hypoxia is a potential stimulator of VEGF expression and HIF‐1 may regulate the hypoxic expression of VEGF in colon cancer.[10](#jcmm14257-bib-0010){ref-type="ref"} We previously demonstrated an association between *miR‐148a* down‐regulation and early relapse in patients with CRC; this finding indicated that *miR‐148a* is a potential biomarker for identifying high‐risk patients with CRC after curative resection.[11](#jcmm14257-bib-0011){ref-type="ref"}

Tumour angiogenesis is required for tumour development and growth and HIF‐1α plays a pivotal role in this process.[12](#jcmm14257-bib-0012){ref-type="ref"} Vascular endothelial growth factor is a target gene of HIF‐1α. Hypoxia‐inducible factor‐1α regulates VEGF expression at the transcriptional level.[13](#jcmm14257-bib-0013){ref-type="ref"} In the present study, we identified *miR‐148a*, which may be related to tumour angiogenesis; identified the signalling pathways that are regulated by *miR‐148a*; and determined the role of *miR‐148a* in the angiogenesis of CRC. Therefore, our findings provide evidence of the role and potential mechanism of *miR‐148a* in regulating CRC angiogenesis and early relapse.

2. MATERIALS AND METHODS {#jcmm14257-sec-0002}
========================

2.1. Study design {#jcmm14257-sec-0003}
-----------------

In our previous study, we confirmed the relationship between the down‐regulation of *miR‐148a* and post‐operative early relapse.[11](#jcmm14257-bib-0011){ref-type="ref"} According to a bioinformatic analysis of pathways,[14](#jcmm14257-bib-0014){ref-type="ref"} *miR‐148a*could affect the function of phosphoryl‐ERK \[pERK\]) and HIF‐1α in other cancers. Hence, we suggested that that *miR‐148a* inhibits VEGF expression by indirectly targeting HIF‐1α and its relevant pathways (Figure [1](#jcmm14257-fig-0001){ref-type="fig"}A). The design of the cell lines study is illustrated in Figure [1](#jcmm14257-fig-0001){ref-type="fig"}B.

![The study hypothesis and design. A, We suggested that that *miR‐148a* inhibits vascular endothelial growth factor (VEGF) through the inactivation of the phosphoryl‐ERK/hypoxia‐inducible factor‐1α (pERK/HIF‐1α) pathway. B, In vitro, we transfected *miR‐148a* into HCT116 and HT29 cells and established stable colorectal cancer (CRC) clones. The protein levels of pERK and HIF‐1α were examined through Western blotting and the mRNA levels of HIF‐1α were tested through RT‐PCR. The protein expression of VEGF was examined through ELISA](JCMM-23-3572-g001){#jcmm14257-fig-0001}

2.2. Cell lines and cell lines authentication test illustration {#jcmm14257-sec-0004}
---------------------------------------------------------------

Before the selection of cell lines, we tried to use *miR‐148a* for transfection and proliferation in five cell lines: HCT116, HT29, SW480, SW620 and Caco‐2. The results demonstrated that the HCT116 and HT29 cells showed fold changes after transfection and relative proliferation was significant altered (Figure [S1](#jcmm14257-sup-0002){ref-type="supplementary-material"}A,B) and activation of the *RAS‐RAF*pathway has been reported to be associated with increased VEGF‐induced angiogenesis. For exploring the role of *miR‐148a* in *BRAF*mutation (HT29 cell) and *KRAS* mutation (HCT116 cell), we chose these two cell lines for experimentation. Human CRC cell lines---HCT116 and HT29 cells---were purchased from the Bioresource Collection and Research Center (Hsinchu, Taiwan) and American Type Culture Collection (Manassas, VA) respectively. All cell lines were cultured in DMEM (Gibco, Grand Island, NY) supplemented with 10% foetal bovine serum (Gibco), 100 IU/mL penicillin (Gibco) and 100 µg/mL streptomycin (Gibco) in a humid atmosphere containing 5% CO~2~ at 37°C. Human umbilical vein endothelial cell was a component of Angiogenesis Starter Kit (Thermo Fisher Scientific, Inc, Waltham, MA).

On delivery from provider, the HCT116 and HT29 cell lines were resuscitated and cultured for 2 weeks and then subjected to transfection with pCDH vector (cDNA Cloning and Expression Lentivectors) (System Biosciences, Palo Alto, CA) expressing *miR‐148a*. The transfected cell lines were then used for experiments afterwards. According to the manufacturers manual statement, after transduction in target cells, the pCDH expression construct can integrate into genomic DNA to provide stable, long‐term expression of the target gene. This genomic integration of expression construct would make transfected cell\'s genome appear different from their wild‐type. Cell line authentication test will no longer, therefore, identify the pCDH transfected cell as original genomic status. As genomic changes were expected, the cell lines used in this study were not subjected to authentication test.

2.3. Patient tissue samples {#jcmm14257-sec-0005}
---------------------------

For proving the expression correlation of *miR‐148a* and target protein level, we re‐analysed the expression level of *miR‐148a* in the first cohort of 110 patients[11](#jcmm14257-bib-0011){ref-type="ref"} and 63 CRC patients who underwent radical resection were enrolled. Among these patients, 28 were post‐operative early relapse patients with *miR‐148a*non‐overexpression and 35 were post‐operative non‐early relapse patients with *miR‐148a*overexpression. Early relapse was defined as local recurrence (tumor growth restricted to the anastomosis or the region of the primary operation) or distant metastasis (distant metastasis or diffuse peritoneal seeding) within one year after radical resection, and the patients who relapsed after the first year or did not relapse were placed into the non‐early relapse group.[3](#jcmm14257-bib-0003){ref-type="ref"}, [11](#jcmm14257-bib-0011){ref-type="ref"}, [15](#jcmm14257-bib-0015){ref-type="ref"} Written informed consent was obtained from all participants after they had been completely informed of the study protocols and that research was carried out according to the World Medical Association Declaration of Helsinki. This study was approved by the institutional review board of Kaohsiung Medical University Hospital (KMUHIRB‐2012‐03‐02(II)). All methods were performed in accordance with the relevant guidelines and regulations.

2.4. Construction of *miR‐148a* overexpressing constructs {#jcmm14257-sec-0006}
---------------------------------------------------------

A pCDH vector (System Biosciences) was used as an *miR‐148a* overexpression system for assessing the functional consequences of *miR‐148a* overexpression. We constructed the pCDH--*miR‐148a* plasmid by inserting the *miR‐148a* polymerase chain reaction (PCR) product into the multiple cloning sites. The sequences of the primers for *miR‐148a* were GCCTGAATTCATGCTTTTAACGAGTTATTCTTC and CTAGGCGGCCGCGCCTTGCCCCTCCCCCAAGGA. The forward primers were extended at the 5′ end to include the GAATTC sequence and the reverse primers were elongated at their 5′ end to include the GCGGCCGC sequence, which created the *EcoR1* and *Not1* restriction sites respectively. The constructs were confirmed through direct DNA sequencing.

2.5. Establishment of a stable clone {#jcmm14257-sec-0007}
------------------------------------

The HCT116 and HT29 cells (5 × 10^5^) were seeded and transfected with 400 ng of the constructs (either the negative scrambled pCDH vector or the pCDH--*miR‐148a* plasmid) by using Lipofectamine 2000 (Thermo Fisher Scientific). To select stably transfected HCT116 and HT29 cells containing the pCDH‐negative control or pCDH--*miR‐148a* plasmid, the cells were cultured over 4 weeks in standard culture media supplemented with an additional 12 µg/mL puromycin (Sigma‐Aldrich Inc, St. Louis, MO). Confirmation of stable transfection of the plasmids was obtained using a miRNA real‐time quantitative PCR (RT‐qPCR) assay (Figure [S1](#jcmm14257-sup-0002){ref-type="supplementary-material"}).

2.6. *miR‐148a* expression levels in CRC cell lines {#jcmm14257-sec-0008}
---------------------------------------------------

The TaqMan miR RT‐qPCR assay (Applied Biosystems, Foster City, CA) was used to quantify the levels of *miR‐148a*. RT‐qPCR was performed with the Applied Biosystems 7900HT Real‐Time PCR System (Applied Biosystems) according to the default thermal cycling conditions of the ABI 7900 Sequence Detection System 2.4 (Applied Biosystems). The relative expression levels of *miR‐148a* were normalized to that of the internal control U6 snRNA by using the equation log10 (2^−ΔCt^), where ΔCt = Ct*~miR‐148a~* − Ct~U6~.

2.7. RNA extraction and cDNA preparation {#jcmm14257-sec-0009}
----------------------------------------

Approximately 10^7^ cells were harvested from culture plates using trypsin. Total RNA, including mRNAs and miRs, was purified using Qiagen RNAeasy Columns (Qiagen, Hamburg, Germany) according to the manufacturer\'s protocols. For the miR assay, the cDNA of each miR was synthesized with a unique primer (Applied Biosystems) by using 20 ng of total RNA. For the mRNA quantitative assay, cDNAs were synthesized from 1 μg of total RNA with random hexamer primers by using Reverse Transcriptase (Applied Biosystems).

2.8. mRNA expression levels {#jcmm14257-sec-0010}
---------------------------

For the mRNA quantitative assay, RT‐qPCR with SYBR Green (Applied Biosystems) was performed with the Applied Biosystems 7900HT Real‐Time PCR System (Applied Biosystems) according to the default thermal cycling conditions of the ABI 7900 Sequence Detection System 2.4 (Applied Biosystems). The relative expression levels of mRNA were normalized to those of the internal control glyceraldehyde 3‐phosphate dehydrogenase (GAPDH) by using the equation log10 (2^−ΔCt^), where ΔCt = Ct~mRNA~ -- Ct~GAPDH~.

2.9. Western blotting {#jcmm14257-sec-0011}
---------------------

Total cell lysates (20 μg) were analysed using sodium dodecyl sulphate--polyacrylamide gel electrophoresis on a 12% gel. After electroblotting onto the nitrocellulose membrane, the membranes were blocked with non‐fat dry milk for 2 hours at room temperature. The membranes were then washed three times with phosphate‐buffered saline (PBS) containing Tween 20 and subsequently incubated with primary antibodies (Abcam plc, Cambridge, England, UK) at 4°C overnight. Anti‐HIF‐1α and anti‐pERK antibody were used at 1:2000 and 1:3000 dilutions respectively. The membranes were then washed with PBS--Tween 20 three times and incubated with a 1:8000 dilution of peroxidase‐linked anti‐mouse IgG (Amersham Biosciences, Piscataway, NJ) for 1 hour at room temperature. After the membranes were washed with PBS‐Tween 20, the bands were detected using a SuperSignal^TM^ West Femto Maximum Sensitivity Substrate (Applied Biosystems).

2.10. Enzyme‐linked immunosorbent assay {#jcmm14257-sec-0012}
---------------------------------------

Vascular endothelial growth factor protein levels in the cell culture medium of CRC cell lines transfected with *miR‐148a* vector were compared with the levels in the medium of control cells. VEGF levels were determined using a VEGF ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer\'s protocol. Briefly, 100 μL of cell culture medium was placed on a microplate that had been pre‐coated with VEGF‐capture antibody at 4°C overnight and the plate was incubated at room temperature for 3 hours. Thereafter, the wells were emptied and rinsed five times with washing buffer. The wells were then incubated with the VEGF detection conjugate. Finally, the plate absorbance was measured at a wavelength of 450 nm.

2.11. Immunohistochemistry {#jcmm14257-sec-0013}
--------------------------

Formalin‐fixed, paraffin‐embedded blocks of CRC were collected. All 4‐μm sections were dried, deparaffinized and rehydrated and heat‐mediated antigen retrieval was performed by boiling under pressure in Target Retrieval Buffer (Leica, pH 6.0; Abcam, pH 9.0; and DAKO, pH 9.0 respectively) for 8 minutes. Three percent hydrogen peroxide was also used for 5 minutes to block endogenous peroxidase activity at room temperature and the slides were washed with Tris buffer solution. Immunohistochemistry (IHC) was performed with anti‐HIF‐1α (1:300; Abcam) and anti‐VEGF (1:200; Santa Cruz Biotechnology, Inc, Dallas, TX) as the primary antibodies. Positive and negative control sections were included in each quality control run. The degree of immunostaining was reviewed and scored by two pathologists.

The assessment of HIF‐1α and VEGF were based on the previous study studies.[16](#jcmm14257-bib-0016){ref-type="ref"}, [17](#jcmm14257-bib-0017){ref-type="ref"} Tumour cell immunoreactivity for HIF‐1α was scored according to the nuclear staining. Both percentage of positive stained tumour cells and the staining intensity were taken into account to determine the expression of HIF‐1α. The percentage of positive cells was rated as follows: 1 point, ≦10% positive tumour cells; 2 points, 11%‐50% positive cells; 3 points, 51%‐80% positive cells; and 4 points, ≧81% positive cells. The staining intensity was rated as follows: 1 point, weak intensity; 2 points, moderate intensity; and 3 points, strong intensity. The sum of the two parameters varied between 2 and 7. For statistical reasons, tumours were then scored according to a two‐scale system: low reactivity (non‐overexpression) denoting tumours with scoring ≦5points and high reactivity (overexpression) denoting tumours with scoring 6‐7 points. For VEGF immunoreactivity was detected in the cytoplasm of the cells. The IHC score was calculated by adding the percentage of positively stained cells to the staining intensity. The percentage of positive cells ranged between 0 and 3, ie 0, if less than 10% of tumour cells were stained; 1, if 10%‐25% of tumour cells were stained; 2, if 25%‐50% were positive; and 3, if \>50% were positive. The staining intensity was scored as: 0, negative immunoreaction; 1, weak intensity; 2, moderate intensity; and 3, strong intensity. The sum of the two parameters varied between 0 and 6. In our study, we considered the statistical convenience and divided into low reactivity (non‐overexpression), scoring ≦4 points and high reactivity (overexpression), scoring 5‐6 points.

2.12. Human umbilical vein endothelial cell tube formation assay {#jcmm14257-sec-0014}
----------------------------------------------------------------

Tube formation experiments were performed with an Angiogenesis Starter Kit (Applied Biosystems) according to the manufacturer\'s manual. Human umbilical vein endothelial cells (HUVECs) seeded on the gel were cultured for 24 hours with the conditioned medium collected from the transfected HCT116 or HT29 cells. Cells were stained using a PKH26 Red Fluorescent Cell Linker Mini Kit (Sigma‐Aldrich Inc) for microscopic visualization. Photographs were obtained using NIS‐Elements imaging software version 3.22.14 connected to the Eclipse Ti‐U inverted microscope system (Nikon Instruments Inc, Melville, NY). After overnight incubation at 37°C, the plates were photographed and the extent of tube formation was assessed.

2.13. Luciferase assay {#jcmm14257-sec-0015}
----------------------

pLightSwith‐HIF‐1α 3ʹUTR (Untranslated regions) luciferase reporter plasmid was purchased from Active Motif (Carlsbad, CA). For transfection, cells were seed to yield 80% confluence in 96 well plates. The next day, cells were co‐transfected with either pLightswitch‐HIF‐1α 3ʹUTR or pLightswitch 3ʹUTR luciferase reporter plasmid and cypridina control construct. Transfections were performance using Lipofectamine 2000 (Thermo Fisher Scientific) following manufacturers instruction. Luciferase activities were measured 48 hours after transfection using the LightSwitch Dual Assay system (Active Motif) by BioTek FLx800 Multi‐Detection Microplate Reader (BioTek, Winooski, VT).

2.14. Inhibition of HIF‐1α and VEGF expression by *miR‐148a* in the hypoxic condition {#jcmm14257-sec-0016}
-------------------------------------------------------------------------------------

From the previous study demonstrated by Seo et  al, CoCl~2~ is a hypoxia mimetic agent.[18](#jcmm14257-bib-0018){ref-type="ref"} Therefore, we used the CoCl~2~ to create a hypoxic culture condition and revealed the ability of inhibition of HIF‐1α and VEGF expression by *miR‐148a* under the hypoxic culture medium.

2.15. In vivo animal study {#jcmm14257-sec-0017}
--------------------------

Four‐week‐old Balb/c nude mice (bodyweight 12.6--15.6 g) were purchased from BioLasco Taiwan, Ltd. (Taipei, Taiwan) and maintained in a specific pathogen‐free environment (certificate no. 26‐99S029). At 6 weeks of age, each nude mouse was injected subcutaneously in the neck area with 1 × 10^7^ HCT116 (either NC or *OmiRNA‐148a*; n = 3 per transfected cell line) and 1 × 10^7^ HT29 (either NC or *OmiRNA‐148a*; n = 3 per transfected cell line). Mouse weight and tumour volume (V) were measured every Monday, Wednesday and Friday. Volume was calculated using the following formula: V = 0.5 × length (mm) × width^2^ (mm^2^).[19](#jcmm14257-bib-0019){ref-type="ref"} The animals were killed 3 weeks after the tumour cells had been seeded. Tumour burdens were analysed and counted immediately without prior fixation.

2.16. Statistical analysis {#jcmm14257-sec-0018}
--------------------------

A chi‐square test was used to analyse differences between the two groups (early relapse vs non‐early relapse). Data are presented as the mean ± SD of three independent experiments. All statistical analyses were performed with the Statistical Package for the Social Sciences 19.0 ([spss]{.smallcaps} Inc, Chicago, IL). A two‐tailed *P* \< 0.05 was considered statistically significant.

3. RESULTS {#jcmm14257-sec-0019}
==========

3.1. *miRNA‐148a* inhibited the activation of pERK and HIF‐1α {#jcmm14257-sec-0020}
-------------------------------------------------------------

To investigate the effect of *miRNA‐148a* on the activation of ERK, we demonstrated that the protein level of pERK was prominently suppressed in the HCT116 and HT29 colon cell lines that expressed *miR‐148a*(Figure [2](#jcmm14257-fig-0002){ref-type="fig"}A,B; *P* = 0.001 and 0.022 respectively). In addition, the protein levels of HIF‐1α expression (Figure [2](#jcmm14257-fig-0002){ref-type="fig"}A,C; *P* = 0.03 and 0.008 respectively) were suppressed, indicating that *miR‐148a* might inhibit HIF‐1α expression and its functionality by decreasing downstream pERK activation.

![The protein levels of phosphoryl‐ERK (pERK) and hypoxia‐inducible factor‐1α (HIF‐1α) in HCT116 and HT29 cell lines were examined through Western blotting. A, The protein levels of pERK and HIF‐1α were significantly decreased under overexpression of *miR‐148a*. (Full‐length blots/gels are presented in Figure [S4](#jcmm14257-sup-0002){ref-type="supplementary-material"}). B, The protein expression of pERK was significantly down‐regulated in HCT116 and HT29 cell lines (*P* = 0.001 and 0.022 respectively). C, The protein expression of HIF‐1α was significantly inhibited in HCT116 and HT29 cell lines (*P* = 0.03 and 0.008 respectively)](JCMM-23-3572-g002){#jcmm14257-fig-0002}

3.2. HIF‐1α acts as an indirect target of *miR‐148a* {#jcmm14257-sec-0021}
----------------------------------------------------

To determine whether HIF‐1α was a target gene of *miR‐148a*, we compared the mRNA and protein levels of HIF‐1α between cells with *miR‐148a* overexpression and non‐overexpression. The overexpression of *miR‐148a* greatly decreased HIF‐1α expression in the HCT116 and HT29 cell lines, as detected using PCR (Figure [3](#jcmm14257-fig-0003){ref-type="fig"}A; *P* = 0.0026 and 0.0424 respectively) and Western blotting (Figure [2](#jcmm14257-fig-0002){ref-type="fig"}C; *P* = 0.03 and 0.008 respectively), suggesting that HIF‐1α is a downstream target gene of *miR‐148a*. Furthermore, we also demonstrated that HIF‐1α was not directly target gene of *miR‐148a* using the luciferase assay in the both colon cancer cell lines (Figure [S2](#jcmm14257-sup-0002){ref-type="supplementary-material"}).

![A, *miR‐148a* indirectly targeted hypoxia‐inducible factor‐1α (HIF‐1α) in HCT116 and HT29 cells. *miR‐148a* significantly inhibited the mRNA expression of HIF‐1α in HCT116 and HT29 cells (*P* = 0.0026 and 0.0424 respectively). B, vascular endothelial growth factor (VEGF) secretion was significantly inhibited by *miR‐148a* in HCT116 and HT29 cells, as detected through ELISA (*P = *0.0042 and 0.000 76 respectively)](JCMM-23-3572-g003){#jcmm14257-fig-0003}

3.3. Expression of *miR‐148a* curbs VEGF secretion in CRC cell lines under hypoxic and no hypoxic conditions {#jcmm14257-sec-0022}
------------------------------------------------------------------------------------------------------------

The secretion levels of VEGF were examined through ELISA in the colon cancer cell lines, HCT116 and HT29. VEGF secretion was significantly down‐regulated in the two CRC cell lines compared with in the control (Figure [3](#jcmm14257-fig-0003){ref-type="fig"}B; *P* = 0.0042 and *P* = 0.000 76), suggesting that VEGF secretion is inhibited by the overexpression of *miR‐148a*.

In the hypoxic culture condition, we also revealed that *miR‐148a* could significantly inhibit the expressions of HIF‐1α and VEGF in HCT116 (*P* = 0.0007 & 0.02 respectively; Figure [S3](#jcmm14257-sup-0002){ref-type="supplementary-material"}A) and in HT29 (*P* = 0.045 & 0.02 respectively; Figure [S3](#jcmm14257-sup-0002){ref-type="supplementary-material"}B).

3.4. Expression of *miR‐148a* curbs VEGF expression in CRC tissue samples {#jcmm14257-sec-0023}
-------------------------------------------------------------------------

The demographic data of the patients enrolled in this study are presented in Table [1](#jcmm14257-tbl-0001){ref-type="table"}. A strong inverse correlation was observed between *miR‐148a* expression levels and HIF‐1α and VEGF expression in CRC tissue samples, as evaluated through IHC staining (Table [2](#jcmm14257-tbl-0002){ref-type="table"}; *P* = 0.002 and 0.004 respectively). The overexpression of *miR‐148a* reversed the protein expression of VEGF and HIF‐1α in the tissue samples, as detected through IHC staining (Figure [4](#jcmm14257-fig-0004){ref-type="fig"}A). These results demonstrate that overexpression of *miR‐148a* prominently inhibits VEGF expression in vitro and in vivo.

###### 

Clinicopathologic features of 63 enrolled colorectal cancer patients

  Number of patients    Early relapsed with *miR‐148a* non‐overexpression   Non‐early relapsed with *miR‐148a* overexpression   *P*‐value
  --------------------- --------------------------------------------------- --------------------------------------------------- -----------
  Gender                                                                                                                        0.645
  Male                  16 (57.2)                                           22 (62.8)                                           
  Female                12 (42.8)                                           13 (37.2)                                           
  Age (y/o)                                                                                                                     0.759
  ≧65                   19 (67.8)                                           25 (71.4)                                           
  \<65                  9 (32.2)                                            10 (28.6)                                           
  Location                                                                                                                      0.271
  Colon                 19 (67.8)                                           28 (80.0)                                           
  Rectum                9 (32.2)                                            7 (20.0)                                            
  Stage                                                                                                                         0.819
  II                    16 (57.2)                                           21 (60.0)                                           
  III                   12 (42.8)                                           14 (40.0)                                           
  Tumour size (cm)                                                                                                              0.260
  ≧5                    16 (57.2)                                           15 (42.9)                                           
  \<5                   12 (42.8)                                           20 (57.1)                                           
  Tumour depth                                                                                                                  0.354
  T2                    0 (0)                                               2 (5.8)                                             
  T3                    26 (92.8)                                           29 (82.6)                                           
  T4                    2 (7.2)                                             4 (11.6)                                            
  Vascular invasion                                                                                                             0.605
  Yes                   8 (28.6)                                            8 (22.9)                                            
  No                    20 (71.4)                                           27 (77.1)                                           
  Perineural invasion                                                                                                           0.085
  Yes                   8 (28.6)                                            4 (11.5)                                            
  No                    20 (71.4)                                           31 (88.5)                                           
  Tumour grade                                                                                                                  0.469
  MD                    23 (82.1)                                           31 (88.5)                                           
  PD                    5 (17.9)                                            4 (11.5)                                            
  Histology                                                                                                                     0.466
  A                     25 (89.2)                                           33 (94.2)                                           
  M                     3 (10.8)                                            2 (5.8)                                             

A, adenocarcinoma; M, mucinous carcinom; MD, moderately differentiated; PD, poorly differentiated.

John Wiley & Sons, Ltd

###### 

Relationship between HIF‐1α/VEGF expressions and *miR‐148a* in the 63 CRC patients by using immunohistochemical staining

                       *miR‐148a* expression   *P*‐value   
  -------------------- ----------------------- ----------- -------
  Number of patients   28                      35          
  HIF‐1α                                                   0.002
  Non‐overexpression   14 (50.0)               30 (85.7)   
  Overexpression       14 (50.0)               5 (14.3)    
  VEGF                                                     0.004
  Non‐overexpression   6 (21.4)                20 (57.1)   
  Overexpression       22 (78.6)               15 (42.9)   

CRC, colorectal cancer; HIF‐1α, hypoxia‐inducible factor‐1α; VEGF, vascular endothelial growth factor.

John Wiley & Sons, Ltd

![The role of *miR‐148a* in angiogenesis. A, vascular endothelial growth factor (VEGF) and hypoxia‐inducible factor‐1α (HIF‐1α) proteins were stained in the cytoplasm of tumour cells (shown in brown) and assessed through immunohistochemistry staining. *miR‐148a* suppressed the expression of VEGF and HIF‐1α. Left panel shows VEGF (top: low expression; bottom: high expression; 200X). Right panel shows HIF‐1α (top: low expression; bottom: high expression; 200X). B, *miR‐148a* significantly destroyed human umbilical vein endothelial cells tube formation in the HCT116 (top) and HT29 (bottom) cell lines](JCMM-23-3572-g004){#jcmm14257-fig-0004}

3.5. HUVEC tube formation assay {#jcmm14257-sec-0024}
-------------------------------

The HUVEC tube formation assay revealed that *miR‐148a* inhibited angiogenesis in both CRC cell lines (Figure [4](#jcmm14257-fig-0004){ref-type="fig"}B). The existence of *miR‐148a* could obliterate the interlocking of vessels. These results demonstrated that overexpression of *miR‐148a* inhibits vein cell tube formation. The results of angiogenesis are actually not quantitative although many statistical charts are included in published literature. The angiogenesis measurement is largely dependent on software setting and measurement changes with setting change. They are better to be considered as visible results as long as difference can be seen between two pictures. However, the statistical charts can be good adjuvant data (*P* = 0.02 in HCT116 cell line and *P* = 0.03 in HT29 cell line; Figures [S4](#jcmm14257-sup-0002){ref-type="supplementary-material"} and [S5](#jcmm14257-sup-0002){ref-type="supplementary-material"}).

3.6. In vivo animal study: Effects of *miR‐148a* overexpression in nude mice {#jcmm14257-sec-0025}
----------------------------------------------------------------------------

To validate the role of *miR‐148a* in tumourigenesis, we determined the effects of *miR‐148a* overexpression on tumour growth in vivo. The *OmiR‐148a* and NC clones with scrambled pCDH‐NC were injected subcutaneously to induce tumour growth in nude mice. The tumours became palpable 7 days after inoculation and were allowed to grow until the end of the third week. Mice that received *OmiR‐148a*cells had significantly smaller cancer lumps than those that received pCDH‐NC cells either in HCT116 or HT29. This in vivo result provides additional support that overexpression of *miR‐148a* results in less tumour cell proliferation in experimental animals (*P* = 0.0007 and 0.0037 in the HCT116 and HT29 cell lines respectively; Figure [S6](#jcmm14257-sup-0002){ref-type="supplementary-material"}A,B).

4. DISCUSSION {#jcmm14257-sec-0026}
=============

A novel finding of the present study is that *miR‐148a* can inhibit the secretion of VEGF through the indirect down‐regulation of HIF‐1α and its relevant pathways. Even under hypoxic condition, we also confirmed that *miR‐148a* efficiently inhibited the expression of HIF‐1α and VEGF. Regardless of in vitro or in vivo conditions, we re‐verified that *miR‐148a* has the ability to inhibit angiogenesis in CRC.

Angiogenesis is a complex process through which new blood vessels are formed from an endothelial precursor. It is a critical step in cancer progression and is considered one of the hallmarks of cancer.[1](#jcmm14257-bib-0001){ref-type="ref"} This process is mediated through a group of ligands and receptors that are tightly regulated.[20](#jcmm14257-bib-0020){ref-type="ref"}, [21](#jcmm14257-bib-0021){ref-type="ref"} Hypoxia‐inducible factor‐1α and VEGF are important regulators of angiogenesis.[22](#jcmm14257-bib-0022){ref-type="ref"} Hypoxia‐inducible factor‐1α activates expression of the VEGF gene by binding to the hypoxia response element in the VEGF promoter region.[23](#jcmm14257-bib-0023){ref-type="ref"} Hypoxia‐inducible factor‐1α and VEGF are major regulators of angiogenesis[24](#jcmm14257-bib-0024){ref-type="ref"} and are important in tumour progression.[25](#jcmm14257-bib-0025){ref-type="ref"} As small non‐coding RNAs, *miRNAs* play a crucial role in CRC tumourigenesis and progression[26](#jcmm14257-bib-0026){ref-type="ref"} and perform their functions by modulating the expression of their target genes. We previously demonstrated that *miR‐148a* inhibits the early relapse of CRC and resulted in reduced tumour growth in animal model of CRC[11](#jcmm14257-bib-0011){ref-type="ref"} and that VEGF can promote early relapse.[27](#jcmm14257-bib-0027){ref-type="ref"} In 2013, Xu et  al demonstrated that down‐regulation of *miR‐148a*activated the ERK signalling pathway to increase HIF‐1α and VEGF expression as well as tumour growth and angiogenesis in breast cancer cell lines.[9](#jcmm14257-bib-0009){ref-type="ref"} Similarly, we demonstrated that overexpression of *miR‐148a* can down‐regulate pERK to inhibit HIF‐1α and VEGF secretion in colon cancer cell lines. Moreover, by using tumour tissue samples from CRC patients, we certified that the *miRNA‐148a* level is inversely related to the expression of HIF‐1α and VEGF. The mechanism of *miR‐148a*‐mediated suppression of pERK probably explained that certain growth factors activate RAS which in turn stimulates the RAS/RAF/MEK/ERK kinase cascade. Activated ERK phosphorylates 4E‐BP1, S6K and MAP kinase interacting kinase (MNK). MNK can also phosphorylate eIF‐4E directly. The net result of these signalling events is the increased rate of mRNA translation into HIF‐1α protein. Interestingly, ERK is not only involved in regulation of HIF‐1α synthesis but also its transcriptional activation. ERK phosphorylates the co‐activator CBP/p300, so it increases HIF‐1α/p300 complex formation and thus stimulates its transcriptional activation function.[28](#jcmm14257-bib-0028){ref-type="ref"}

In recent years, many studies have revealed that the aberrant expression of miRNA is closely related to oncogenesis and this is now an intense field of study. *miR‐148a*is aberrantly expressed in various cancers and has been identified as an oncogenic or tumour suppressor with crucial roles in the molecular mechanisms of oncogenesis.[8](#jcmm14257-bib-0008){ref-type="ref"} In the some studies, it was also proven that *miR148a*‐mediated suppression of tumour growth and tumour vascular formation existed in vivo experiments.[9](#jcmm14257-bib-0009){ref-type="ref"}, [11](#jcmm14257-bib-0011){ref-type="ref"} Overexpression of *miR‐148a* was reported to inhibit ERBB3 expression, block downstream pathway activation (including the activation of AKT, ERK1/2 and p70S6K1) and decrease HIF‐1α expression in breast cancer cell lines.[29](#jcmm14257-bib-0029){ref-type="ref"} Some VEGF‐targeted *miRNAs*, including *miR‐93*,[2](#jcmm14257-bib-0002){ref-type="ref"} *miR‐203*,[30](#jcmm14257-bib-0030){ref-type="ref"} *miR‐26a*,[31](#jcmm14257-bib-0031){ref-type="ref"} *miR‐497*,[32](#jcmm14257-bib-0032){ref-type="ref"} *miR‐199a‐5p* [33](#jcmm14257-bib-0033){ref-type="ref"} and *miR‐140‐5p* [26](#jcmm14257-bib-0026){ref-type="ref"} have an antitumour effect in various human cancers. According to several algorithms, we initially suggested that that *miR‐148a* targets HIF‐1α to down‐regulate VEGF. In the present study, we demonstrated that overexpression of *miR‐148a* significantly reduced VEGF protein secretion in vitro and in vivo through the inhibition of HIF‐1α. VEGF expression had a remarkable inverse correlation with *miR‐148a* expression in CRC tissue and cell lines. This regulation is independent of ERK modulation by *RAS/RAF* pathway. Therefore, the effects of *RAS/RAF* mutation on ERK regulation in HCT116 and HT29 cells may be bypassed. Finally, we suggested that *miR‐148a* down‐regulates VEGF through the pERK/HIF‐1α pathway in CRC and might be closely associated with early relapse of CRC. However, other upstream pathways for ERK regulation may be also considered and further studies should be carried out.

The cytokine VEGF is an angiogenic factor implicated in processes such as organ development, wound healing, tissue regeneration, endothelial cell growth and vessel permeability.[34](#jcmm14257-bib-0034){ref-type="ref"} In some solid tumours, overexpression of VEGF is associated with increased angiogenesis, growth and/or metastasis.[35](#jcmm14257-bib-0035){ref-type="ref"}, [36](#jcmm14257-bib-0036){ref-type="ref"} Researchers have also demonstrated that VEGF is not only a promising therapeutic target but also seems to be a poor prognostic factor for several cancers.[37](#jcmm14257-bib-0037){ref-type="ref"}, [38](#jcmm14257-bib-0038){ref-type="ref"}, [39](#jcmm14257-bib-0039){ref-type="ref"} In CRC, VEGF‐signalling‐induced neovascularity is a key mediator of tumour angiogenesis, invasion and dissemination.[40](#jcmm14257-bib-0040){ref-type="ref"} VEGF level is increased in CRC and associated with a malignancy\'s increased ability to spread and a poorer prognosis.[38](#jcmm14257-bib-0038){ref-type="ref"}, [41](#jcmm14257-bib-0041){ref-type="ref"} Previously, we demonstrated that VEGF played an important role in the post‐operative early relapse of CRC patients, following radical resection.[27](#jcmm14257-bib-0027){ref-type="ref"} In the current study, we further demonstrated a negative correlation between *miR‐148a* and VEGF expression or secretion in the corresponding colorectal tissues and CRC cancer cell lines.

In conclusion, our study revealed that *miR‐148a* down‐regulated VEGF through the pERK/HIF‐1α pathway. Through the inhibition of VEGF, overexpression of *miR‐148a* might reduce post‐operative early relapse in CRC patients. By using the informatics analysis and luciferase assay, we found that HIF‐1α is not a potential directly target for *miR‐148a*. Therefore, we believe that *miR‐148a* does not directly bind to the 3ʹ‐UTR region of HIF‐1α, but by inhibiting the expression of other genes. However, we would certainly take into consideration of investigating the direct target genes and the mechanism of reduced ERK phosphorylation in our future studies.
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